Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Balancing speed, science and regulatory requirements in oncology drug development

This article has been updated

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 10 October 2022

    In the version of this article initially published, discussion in the fifth paragraph referring to “bispecific antibodies” originally used the term “BiTEs”; the text has been updated in the HTML and PDF versions of the article.


  1. Anonymous. BioSpace (2021).

  2. Snyder, A. et al. Preprint at medRxiv (2022).

  3. Sachs, J. R. et al. Clin. Cancer Res. 22, 1318–1324 (2016).

    Article  CAS  PubMed  Google Scholar 

  4. Villela, L. R. et al. Pharmacotherapy 26, 641–654 (2006).

    Article  CAS  PubMed  Google Scholar 

  5. Jabbour, E. et al. Nat. Rev. Clin. Oncol. 18, 418–433 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Abramson, J. S. et al. Lancet 396, 839–852 (2020).

    Article  PubMed  Google Scholar 

  7. Adans, B. Fierce Biotech (2020).

  8. Hosseini, I. et al. NPJ Syst. Biol. Appl. 6, 28 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Goonewardene, A. et al. Truist Securities Research (June 2022); available upon request to authors.

Download references

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Alexandra Snyder or Priti S. Hegde.

Ethics declarations

Competing interests

A.S. is an employee of Generate Biomedicines and owns shares in Allogene and Merck. P.S.H. is an employee of Foundation Medicine, Inc. and owns shares in Roche, Bolt Therapeutics and TCR2. D.D. is an employee of and owns shares in Merck, Inc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Snyder, A., De Alwis, D., Goonewardene, A. et al. Balancing speed, science and regulatory requirements in oncology drug development. Nat Med 28, 2234–2235 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer